Blood-Brain-CSF Barriers, CNS Homeostasis, Drug Delivery

这项建议是要求提供资金，以支持将于2002年7月举行的戈登研究会议。预定的会议是第二次戈登研究会议的障碍，中枢神经系统。这个戈登研究会议是作为一个催化剂，研究人员之间的互动，从各种f学科工作的问题，血脑和血CSF屏障的健康疾病。在这一领域的研究已经导致开发新的治疗方法，用于治疗中风，头部创伤，神经变性，脑炎症和脑肿瘤，仅举几例。虽然这些研究领域的一部分在几个国家和国际研究会议上有代表，但在该领域工作的科学家很少有机会聚集在一起，具体集中关注与CNS障碍有关的问题。即将举行的第二届CNS戈登研究会议的副标题是“血脑CSF屏障，CNS稳态和药物输送到大脑”。本次会议的具体重点将包括讨论制药行业在将治疗药物靶向CNS方面面临的一些问题和组织，以及讨论血脑屏障和血CSF屏障领域目前更广泛的主要发展。这些问题中的大多数涉及克服药物的血脑屏障。为此，来自学术界和制药行业的一些杰出科学家聚集在一起，参加一个令人兴奋的“前沿”会议。其目的是促进新思想的发展及其在基础知识和人类和动物疾病治疗中的应用。发言者是根据他们在该领域的隆起和沟通技巧挑选的。为此目的，它们是从广泛的地理背景中挑选出来的。各届会议的主席是根据他们在该领域的杰出隆起和经验以及众所周知的良好沟通和辩论能力挑选的。 此外，还大力鼓励特别是年轻的博士后和研究生展示海报。预计美国国立卫生研究院赠款的相当一部分将用于资助年轻科学家和主席的出席。还打算在会议期间举行三次公开研讨会/辩论。其中一个已经在“微透析”方面到位。出席本次会议的科学家人数上限为150人。

This proposal is a request for funds toward the support of a Gordon Research Conference to be held in July 2002. The intended meeting is the second Gordon Research Conference on Barriers of the Central Nervous System. This Gordon Research Conference was initiated as a catalyst for interaction among researchers from a variety f disciplines working on issues of blood-brain- and blood-CSF barriers in health disease. Research in this area is already leading to development of new therapeutic approaches for th treatment of stroke, head trauma, neurodegeneration, brain inflammation and brain tumors, to name a fe3w. Although portions of these areas of investigation are represented at several national and international research meetings, there have been few opportunities for scientists working in the field to come together with a specific concentrated focus on issues related to barriers of the CNS. The subtitle of the upcoming second Barriers of the CNS Gordon Research Conference is "Blood-Brain CSF barriers, CNS Homeostasis and Drug Delivery to the Brain". The specific focus of this conference will include discussion of a number of the problems and tissues faced by the Pharmaceutical industry in targeting therapeutic drugs to the CNS as well as discussion of broader current major developments of the blood- brain-barrier and blood-CSF barrier field. Most of these problems concern overcoming the blood-brain barrier to drugs. To this end a number of eminent scientists from academia and from the pharmaceutical industry, are being brought together for an exciting "leading edge" meeting. The intention is to foster the development of new ideas and their application to fundamental knowledge and the treatment of human and animal disease. Speakers have been selected on the basis of their eminence in the field and their communication skills. TO this end they are drawn from a wide geographical background. Chairs of the sessions have been selected on the basis of their considerable eminence and experience in the field and a known ability to communicate and debate well. In addition the presentation of posters is being vigorously encouraged especially by young postdoctoral and research students. It is expected that a considerable proportion of any NIH grant will be used to fund the attendance of young scientists and chairs. It is also intended to have three open workshops/debates during the meeting. One is already in place on "Microdialysis". The maximum permitted attendance at this meeting is 150 scientists.